Vnitr Lek 2022, 68(6):393-397 | DOI: 10.36290/vnl.2022.080

SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction

Jiří Slíva
Ústav farmakologie, 3. lékařská fakulta UK, Praha

Heart failure is highly prevalent in the population and, from a long-term point of view, a disease that is still difficult to treat. Although a number of medicinal solutions are offered in its treatment, there are still large reserves. The drug portfolio has recently been expanded to include the use of SGLT-2 inhibitors, initially for failure with reduced and now also with preserved ejection fraction. The question of the possibility of using these substances is discussed in the text, focusing on a possible explanation of their therapeutic benefit.

Keywords: SGLT-2, heart failure, ejection fraction, gliflozins, empagliflozin.

Accepted: September 23, 2022; Published: October 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction. Vnitr Lek. 2022;68(6):393-397. doi: 10.36290/vnl.2022.080.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. Go to original source... Go to PubMed...
    2. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014 Sep;11(9):507-15. Go to original source... Go to PubMed...
    3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. Go to original source... Go to PubMed...
    4. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011 May 10;123(18):2006-13. Go to original source... Go to PubMed...
    5. Borlaug BA. Defining HFpEF: where do we draw the line? Eur Heart J. 2016 Feb 1;37(5):463- Go to original source... Go to PubMed...
    6. Solomon SD, Claggett B, Lewis EF et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016 Feb 1;37(5):455-62. Go to original source... Go to PubMed...
    7. Lee DS, Gona P, Vasan RS et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009 Jun 23;119(24):3070-7. Go to original source... Go to PubMed...
    8. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state‑of‑the‑art review. Diabetologia. 2018 Oct;61(10):2108-2117. Go to original source... Go to PubMed...
    9. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney, DiS. 2009 May;53(5):875-83. Go to original source... Go to PubMed...
    10. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co‑transport-2 inhibitors in type 2 diabetes: a meta‑analysis of randomized clinical trials. Diabetes Obes Metab. 2014 May;16(5):457-66. Go to original source... Go to PubMed...
    11. Sattar N, McLaren J, Kristensen SL et al. SGLT2 Inhibition and cardiovascular events: why did EMPA‑REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016 Jul;59(7):1333-1339. doi: 10.1007/s00125-016-3956-x. Epub 2016 Apr 25. Erratum in: Diabetologia. 2016 Jul;59(7):1573-4. Go to original source... Go to PubMed...
    12. Lytvyn Y, Bjornstad P, Udell JA et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 Oct 24;136(17):1643-1658. Go to original source... Go to PubMed...
    13. Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. Clin Res Cardiol. 2018 Aug;107(Suppl 2):64-73. Go to original source... Go to PubMed...
    14. Uthman L, Baartscheer A, Bleijlevens B et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018 Mar;61(3):722-726. Go to original source... Go to PubMed...
    15. Baartscheer A, Schumacher CA, Wüst RC et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017 Mar;60(3):568-573. Go to original source... Go to PubMed...
    16. Fernandes GC, Fernandes A, Cardoso R et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta‑analysis of 34 randomized controlled trials. Heart Rhythm. 2021 Jul;18(7):1098-1105. Go to original source... Go to PubMed...
    17. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. Go to original source... Go to PubMed...
    18. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.